Replies to post #145897 on Biotech Values

[DewDiligence]

Re: Bapineuzumab results

…there must not have been a hint of efficacy if they also dropped the patients out of the extension study…

That’s consistent with this statement in the PR:

The [PFE-JNJ] Alliance will expedite the completion of an interim analysis for the on-going, Pfizer-conducted Phase 3 study of ApoE4 carriers (Study 3001) based on the results of Study 302.

[mcbio]

dissappointing for patients. there must not have been a hint of efficacy if they also dropped the patients out of the extension study

Do these results make you more skeptical regarding gantenerumab's chances now (#msg-76820890)?